Market Cap | 1.05B | P/E | - | EPS this Y | 17.00% | Ern Qtrly Grth | - |
Income | -118.48M | Forward P/E | - | EPS next Y | -36.20% | 50D Avg Chg | - |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | - |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -5.00% |
Recommedations | 1.10 | Quick Ratio | 27.47 | Shares Outstanding | 43.19M | 52W Low Chg | 4.00% |
Insider Own | 11.31% | ROA | -19.30% | Shares Float | 29.01M | Beta | - |
Inst Own | 122.87% | ROE | -26.73% | Shares Shorted/Prior | 8.19M/8.19M | Price | 20.81 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 512,264 | Target Price | 85.50 |
Oper. Margin | - | Earnings Date | - | Volume | 153,889 | Change | -2.89% |
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
B of A Securities | Buy | May 10, 24 |
Jefferies | Buy | Mar 6, 24 |
Stifel | Buy | Mar 5, 24 |
Guggenheim | Buy | Mar 5, 24 |
Guggenheim | Buy | Jan 3, 24 |
BTIG | Buy | Dec 20, 23 |
TD Cowen | Outperform | Aug 8, 23 |
Wedbush | Outperform | Aug 8, 23 |
Stifel | Buy | Aug 8, 23 |